Design Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

DSGN$10.65-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Cash Flows

(in thousands)

	Nine Months Ended September 30,
	2024	2023
Cash flows from operating activities
Net loss	$(35,937)	$(55,020)
Reconciliation of net loss to net cash used in operating activities:
Depreciation	447	399
Stock-based compensation	9,601	10,364
Amortization of premiums on investment securities, net	(4,760)	(4,248)
Non-cash lease expense	9	28
Change in operating assets and liabilities:
Prepaid expense and other assets	(379)	1,151
Accounts payable and other liabilities	(2,226)	1,564
Net cash used in operating activities	(33,245)	(45,762)
Cash flows from investing activities
Purchases of investment securities	(165,802)	(150,550)
Proceeds from maturities of investment securities	208,265	197,760
Purchases of property and equipment	(340)	(229)
Net cash provided by investing activities	42,123	46,981
Cash flows from financing activities
Issuance of common stock through employee stock purchase plan	223	206
Proceeds from the exercise of stock options	27	17
Net cash provided by financing activities	250	223
Net increase in cash and cash equivalents	9,128	1,442
Cash and cash equivalents at beginning of period	21,200	26,500
Cash and cash equivalents at end of period	$30,328	$27,942

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.